Science Applications International 1Q Revenue Increases; Maintains FY26 Outlook

Dow Jones
Jun 02, 2025
 

By Denny Jacob

 

Science Applications International posted higher revenue in its latest quarter as the volume of contracts it operated increased, as it maintained its outlook for the fiscal year.

The information-technology services provider logged net income of $68 million, or $1.42 a share, for the first quarter ended May 2, down from $77 million, or $1.48 a share, in the prior-year period.

Stripping out certain one-time items, earnings came in at $1.92 a share. Analysts polled by FactSet expected $2.12 per share.

Revenue edged up to $1.88 billion from $1.85 billion. Analysts polled by FactSet had expected $1.87 billion.

Science Applications said the year-over-year top-line increase was primarily due to a ramp-up in volume on new and existing contracts, partially offset by completed contracts.

"Our performance in the first quarter reflects the steady progress we are making against our enterprise growth strategy despite a still dynamic operating environment," said Chief Executive Toni Townes-Whitley.

Science Applications maintained its outlook for fiscal 2026. The company had previously forecast revenue between $7.60 billion and $7.75 billion, as well as adjusted earnings per share in the range of $9.10 and $9.30.

 

Write to Denny Jacob at denny.jacob@wsj.com

 

(END) Dow Jones Newswires

June 02, 2025 07:15 ET (11:15 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10